IBB, the largest biotechnology ETF by assets, closed around $314 on Tuesday. The ETF celebrated 10 years on the market last month.
More On IBB
IBB tracks the Nasdaq Biotechnology Index and holds almost 160 stocks. The ETF is cap-weighted, meaning it features significant allocations to the largest biotechnology companies.
IBB has lost 8 percent over the past month, sparking fourth-quarter outflows of nearly $223 million. However, the ETF is heavier year-to-date as highlighted by inflows of over $581 million. IBB has over $9.6 billion in assets under management.
More Details
Nearly 82 percent of IBB's roster is classified as biotechnology, but the ETF features some token exposure to pharmaceuticals companies and life sciences firms. Those industry groups combine for almost 18 percent of the fund's weight.
Underscoring the often volatile nature of the biotechnology space, IBB has a three-year standard deviation of 23.7 percent, more than double the comparable metric found on the S&P 500.
IBB charges 0.47 percent per year, or $47 on a $10,000 investment.
Related Links:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
